|
|
|
Effect of Rosuvastatin combined with Ezetimibe in patients with myocardial infarction and its influence on the level of inflammatory factors
|
| WANG Xiang-jie XU Qing-zong ZHANG Xue JIA Bo-han |
| Department of Emergency General Ward,the Third People′s Hospital of Dalian,Liaoning Province,Dalian 116033,China |
|
|
|
|
Abstract Objective To explore the effect of Rosuvastatin combined with Ezetimibe in patients with myocardial infarction and its influence on the level of inflammatory factors.Methods A total of 94 patients with myocardial infarction admitted to the Third People′s Hospital of Dalian from January 2019 to January 2020 were selected as the research subjects and divided into the study group(47 cases)and the control group(47 cases)according to the random number table method.The control group was treated with Rosuvastatin,and the study group was treated with Rosuvastatin combined with Ezetimibe.The inflammatory factor levels(tumor necrosis factor -α[TNF-α],hypersensitive C-reactive protein[hs-CRP]and interleukin 6[IL-6]),treatment effect and blood lipid levels(total cholesterol[TC],triylglycerol[TG],low density lipoprotein cholesterol[LDL-C]),the total incidence of adverse reactions and myocardial enzyme levels(lactate dehydrogenase[LDH],creatine kinase[CK],creatinine kinase isoenzyme[CK-MB])of two groups were compared.Results The levels of TNF-α,hs-CRP and IL-6 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).Before the treatment,there were no statistically significant differences in the levels of TC,TG,LDL-C between the two groups(P>0.05).After the treatment,the levels of TC,TG,LDL-C in the study group were lower than those in the control group,with statistically significant difference(P<0.05).The total incidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Before the treatment,there were no statistically significant differences in the levels of LDH,CK and CK-MB between the two groups(P>0.05).After the treatment,the levels of LDH,CK and CK-MB in the study group were lower than those in the control group,with statistically significant difference(P<0.05).Conclusion Patients with myocardial infarction were treated with Rosuvastatin combined with Ezetimibe,with a certain therapeutic effect,could effectively improve the clinical symptoms in patients with myocardial infarction,at the same time,also can effectively reduce the blood lipid levels in patients with myocardial infarction,inhibiting inflammatory reaction,reduce the adverse reaction condition,high safety,it′s worth popularizing further application in clinic.
|
|
|
|
|
|
| [1] |
谢亚芹，赵娟，康大伟，等．不同剂量瑞舒伐他汀对急性心肌梗死大鼠心肌纤维化的影响及机制[J]．广东医学，2018，39（2）：195－198．
|
| [2] |
朱灿阳，吴丹娜，黎燕峰．瑞舒伐他汀通过抑制炎症反应改善心肌梗死大鼠心功能及心肌纤维化[J]．中国临床药理学杂志，2019，12（16）：1742－1745．
|
| [3] |
Olga Krystufková，Hulejová Hana，Mann HF，et al.Serum levels of B－cell activating factor of the TNF family（BAFF）correlate with anti－Jo－1 autoantibodies levels and disease activity in patients with anti－Jo－1positive polymyositis and dermatomyositis[J].Arthritis Res Ther，2018，20（1）：158．
|
| [4] |
卢婷，陶贵周．前列地尔对直接经皮冠状动脉介入治疗的急性ST 段抬高型心肌梗死患者心肌灌注的影响[J]．中国动脉硬化杂志，2019，27（4）：337－343．
|
| [5] |
曹磊，宋新梅，冯克娜，等．利拉鲁肽干预对急性心肌梗死伴2 型糖尿病患者心室重构及心功能的影响[J]．中华内分泌代谢杂志，2019，35（2）：121－127．
|
| [6] |
Benekos T，Kosmeri C，Vlahos A，et al.Nine－year overview of dyslipidemia management in children with heterozygous familial hypercholesterolemia：a university hospital outpatient lipid clinic project in Northwestern Greece[J].J.Pediatr.Endocrinol.Metab，2020，33（4）：533－538．
|
| [7] |
常超，刘珊，姜河，等．无创通气对急性心肌梗死后心力衰竭大鼠的治疗作用[J]．中华老年医学杂志，2020，39（4）：451－455．
|
| [8] |
姜河，刘珊，宋衍秋，等．无创通气对急性心肌梗死后心力衰竭大鼠的治疗作用及其机制[J]．中华老年医学杂志，2019，38（1）：76－79．
|
| [9] |
张创良，吴清权，陈元椿，等．血必净注射液对急性非ST段抬高型心肌梗死患者cTnT，NT－ProBNP，TNF－α，IL－6，IL－10 和hs－CRP 的影响[J]．中国老年学杂志，2019，39（2）：257－260．
|
| [10] |
Lin CY，Hwang YT，Chen PC，et al.Association of serum levels of 4－tertiary－octylphenol with cardiovascular risk factors and carotid intima－media thickness in adolescents and young adults[J].Environ.Pollut，2019，246（5）：107－113．
|
| [11] |
陈志松，喻卓，曾永利．瑞舒伐他汀对急性心肌梗死大鼠心肌基质金属蛋白及炎症因子的影响[J]．中国比较医学杂志，2019，29（2）：66－71．
|
| [14] |
刘瑞东，王小丽，陈莉莉．血清MCP－1、OPG 水平与急性心肌梗死患者PCI 术后血管再狭窄的关系[J]．山东医药，2019，59（1）：67－69．
|
| [12] |
贺旭东，孙明辉，王志超，等．老年急性心肌梗死患者中血清白细胞介素－6，心肌肌钙蛋白Ⅰ，超敏C 反应蛋白与肿瘤坏死因子－α 水平的变化及临床意义[J]．中国老年学杂志，2018，38（6）：1326－1328．
|
| [13] |
Hong SJ，Jeong HS，Ahn JC，et al.A Phase Ⅲ，Multicenter，Randomized，Double－blind，Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia： IROSETTE（Ildong Rosuvastatin &Ezetimibe for Hypercholesterolemia）Randomized Controlled Trial[J].Clin Ther，2018，40（2）：226－241．
|
| [15] |
Rhee MY，Kim KJ，Kim SH，et al.Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid－lowering Efficacy[J].C Clin Ther，2019，41（12）：2571－2592．
|
|
|
|
